目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s InternalL Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details Of Primary Research
1.4. Information Or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4

Chapter 2. Chapter 2 Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.1.1. Rising Adoption Of Biologics And Biosimilars
3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Challenges Related To Quality Control
3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
3.5. Covid-19 Impact On Bioprocessing And Outsourcing
3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
3.5.2. Supply Chain
3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
3.5.4. Changes In The Long Term

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Growth Hormones
4.1.2. Interferons
4.1.3. Vaccines
4.1.4. Immunostimulating Agents
4.1.5. Others
4.2. Segment Dashboard
4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4.1. Growth Hormones
4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.2. Interferons
4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.3. Vaccines
4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.4. Immunostimulating Agents
4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
4.4.5. Others
4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Mammalian Systems
5.1.2. Microbial Systems
5.1.3. Others
5.2. Segment Dashboard
5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
5.4.1. Mammalian Systems
5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
5.4.2. Microbial Systems
5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
5.4.3. Others
5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.2. Infectious Diseases
6.1.3. Immunological Disorders
6.1.4. Metabolic Disorders
6.1.5. Haematological Disorders
6.1.6. Others
6.2. Segment Dashboard
6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.2. Infectious Diseases
6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.3. Immunological Disorders
6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.4. Metabolic Disorders
6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.5. Haematological Disorders
6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.6.7. South Korea
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
8.3. Major Deals and Strategic Alliances Analysis
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Richter-Helm BioLogics
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Lonza
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Catalent, Inc
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. FUJIFILM Diosynth Biotechnologies
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. WuXi Biologics
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Curia Global, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Batavia Biosciences B.V.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. HALIX B.V.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BIOVIAN
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Enzene Biosciences Ltd
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 4 North America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 5 North America Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 6 U.S. Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 9 Canada Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 10 Canada Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 11 Canada Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 12 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 13 Europe Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 14 Europe Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 15 Europe Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 16 UK Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 17 UK Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 18 UK Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 19 Germany Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 20 Germany Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 21 Germany Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 22 France Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 23 France Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 24 France Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 25 Italy Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 26 Italy Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 27 Italy Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 28 Spain Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 29 Spain Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 30 Spain Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 31 Denmark Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 34 Sweden Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 37 Norway Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 38 Norway Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 39 Norway Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 44 Japan Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 45 Japan Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 46 Japan Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 47 China Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 48 China Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 49 China Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 50 India Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 51 India Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 52 India Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 53 Australia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 54 Australia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 55 Australia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 56 Thailand Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 57 Thailand Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 58 Thailand Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 60 South Korea Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 61 South Korea Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 62 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 65 Brazil Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 66 Brazil Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 68 Mexico Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 69 Mexico Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 71 Argentina Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 72 Argentina Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 74 MEA Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 75 MEA Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 76 MEA Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 77 MEA Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 78 South Africa Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 79 South Africa Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 84 UAE Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 85 UAE Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 86 UAE Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
Table 87 Kuwait Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
Table 88 Kuwait Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Recombinant protein therapeutics CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2022 (USD Billion)
Fig. 16 Ancillary market outlook, 2022 (USD Billion)
Fig. 17 Recombinant protein therapeutics CDMO market dynamics
Fig. 18 Porter’s five forces analysis
Fig. 19 PESTEL analysis
Fig. 20 Recombinant protein therapeutics CDMO market type outlook: Segment dashboard
Fig. 21 Recombinant protein therapeutics CDMO market, by type segment: Market share, 2023 & 2030
Fig. 22 Growth hormones market, 2018 - 2030 (USD Million)
Fig. 23 Interferons market, 2018 - 2030 (USD Million)
Fig. 24 Vaccines market, 2018 - 2030 (USD Million)
Fig. 25 Immunostimulating agents market, 2018 - 2030 (USD Million)
Fig. 26 Others market, 2018 - 2030 (USD Million)
Fig. 27 Recombinant protein therapeutics CDMO market source outlook: Segment dashboard
Fig. 28 Recombinant protein therapeutics CDMO market, by source segment: Market share, 2023 & 2030
Fig. 29 Mammalian systems market, 2018 - 2030 (USD Million)
Fig. 30 Microbial systems market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Recombinant protein therapeutics CDMO market indication outlook: Segment dashboard
Fig. 33 Recombinant protein therapeutics CDMO market, by indication segment: Market share, 2023 & 2030
Fig. 34 Oncology market, 2018 - 2030 (USD Million)
Fig. 35 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 36 Immunological disorders market, 2018 - 2030 (USD Million)
Fig. 37 Metabolic disorders market, 2018 - 2030 (USD Million)
Fig. 38 Haematological disorders market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Regional market: Key takeaways
Fig. 41 Regional marketplace: Key takeaways
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 U.S. recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Canada recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 48 Europe recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 49 Key country dynamics
Fig. 50 UK recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Germany recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 France recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Italy recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Spain recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Sweden recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Denmark recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Norway recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 65 Asia Pacific recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Japan recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 China recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 India recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Australia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Clinical trial approval process in South Korea
Fig. 76 South Korea recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Thailand recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 79 Latin America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 Brazil recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Mexico recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Argentina recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 86 MEA recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 South Africa recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 Saudi Arabia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Clinical trial authorization process UAE
Fig. 93 UAE recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Kuwait recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
Fig. 96 Market participant categorization
Fig. 97 Market participant categorization
Fig. 98 Heat map analysis